Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer

• Published in: Anticancer research Vol. 37; no. 3; pp. 1297 - 1304
• Main Authors: Yoon, Yong Sik, Kim, Chan Wook, Roh, Seon Ae, Cho, Dong Hyung, Kim, Tae Won, Kim, Moon Bo, Kim, Jin Cheon
• Format: Journal Article
• Language: English
• Published: Greece 01.03.2017
• Subjects: Aged; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - metabolism; Drug Screening Assays, Antitumor - methods; Female; Fluorouracil - administration & dosage; Humans; Leucovorin - administration & dosage; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds - administration & dosage; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity; molecular targeted therapy; chemotherapy; treatment outcome; Colorectal adenocarcinoma; histoculture drug-response assay
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.11447

The present study investigated how well the results of integrative tumor-response assay (ITRA) compared to those of clinical response to chemotherapy in patients with metastatic colorectal cancer (CRC). A total of 129 patients with metastatic CRC were prospectively enrolled. ITRA consisted of two sequential histoculture drug-response assays (HDRAs). First-stage HDRAs were performed using 5-fluorouracil with leucovorin and oxaliplatin (FX), or with irinotecan (FR). Second-stage HDRAs (ITRA) were performed for cells surviving after the first-stage HDRA, using FX, FR, and their combinations with bevacizumab and cetuximab. Among 129 patients, 42 (32.6%) completed second-line chemotherapy, results that correlated with those of ITRA. The accuracy of ITRA for predicting response to second-line chemotherapy was 61.9% (26/42), with a sensitivity of 44.4% (8/18) and a specificity of 75% (18/24). Despite its relatively low accuracy, ITRA might be a useful technique for predicting therapeutic efficacy and selecting for appropriate first-line and second-line anticancer regimens for patients.